Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Merkelbach

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Human Mutation|November 22, 2007
RNA-based mutation analysis identifies an unusual MSH6 splicing defect and circumvents PMS2 pseudogene interferenceJ Etzler, A Peyrl, A Zatkova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 8, 2006
No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosisH F Petereit, D Reske, R Pukrop, et al.
BMC Gastroenterology|June 2, 2018
Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowelA Quaas, D Waldschmidt, H Alakus, et al.
Der Urologe. Ausg. A|September 22, 2019
[Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group]N Ortiz-Brüchle, M Muders, M Toma, et al.
The British Journal of Dermatology|February 18, 2020
GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanomaE Livingstone, A Zaremba, S Horn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancerA Kron, C Alidousty, M Scheffler, et al.
ESMO Open|July 15, 2025
Treatment outcome of NSCLC patients with BRAF<sup>non-V600E</sup> mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in GermanyC Kropf-Sanchen, A Rasokat, P Christopoulos, et al.
Der Nervenarzt|May 28, 2021
[Telemedicine in stroke-pertinent to stroke care in Germany]J Barlinn, S Winzer, H Worthmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2022
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)M Janning, J Süptitz, C Albers-Leischner, et al.
ESMO Open|February 13, 2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trialS Michels, B Massutí, I Vasyliv, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Human Mutation|November 22, 2007
RNA-based mutation analysis identifies an unusual MSH6 splicing defect and circumvents PMS2 pseudogene interferenceJ Etzler, A Peyrl, A Zatkova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 8, 2006
No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosisH F Petereit, D Reske, R Pukrop, et al.
BMC Gastroenterology|June 2, 2018
Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowelA Quaas, D Waldschmidt, H Alakus, et al.
Der Urologe. Ausg. A|September 22, 2019
[Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group]N Ortiz-Brüchle, M Muders, M Toma, et al.
The British Journal of Dermatology|February 18, 2020
GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanomaE Livingstone, A Zaremba, S Horn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancerA Kron, C Alidousty, M Scheffler, et al.
ESMO Open|July 15, 2025
Treatment outcome of NSCLC patients with BRAF<sup>non-V600E</sup> mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in GermanyC Kropf-Sanchen, A Rasokat, P Christopoulos, et al.
Der Nervenarzt|May 28, 2021
[Telemedicine in stroke-pertinent to stroke care in Germany]J Barlinn, S Winzer, H Worthmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2022
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)M Janning, J Süptitz, C Albers-Leischner, et al.
ESMO Open|February 13, 2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trialS Michels, B Massutí, I Vasyliv, et al.
Pageof 6